Empagliflozin benefits in patients with heart failure and preserved ejection fraction

被引：0
|
作者：
机构：
来源：
Nature Medicine | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
引用
收藏
页码：2480 / 2481
页数：1
相关论文
共 50 条
  • [41] Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
    Tang, Yi
    Sang, Haiqiang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Hypoxaemia in patients with heart failure and preserved ejection fraction
    Omar, Massar
    Omote, Kazunori
    Sorimachi, Hidemi
    Popovic, Dejana
    Kanwar, Ardaas
    Alogna, Alessio
    Reddy, Yogesh N. V.
    Lim, Kaiser G.
    Shah, Sanjiv J.
    Borlaug, Barry A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (09) : 1593 - 1603
  • [43] Management of patients with heart failure and preserved ejection fraction
    Jasinska-Piadlo, Alicja
    Campbell, Patricia
    HEART, 2023, 109 (11) : 874 - 883
  • [44] Hypoxemia in patients with heart failure and preserved ejection fraction
    Omar, M.
    Omote, K.
    Sorimachi, H.
    Popovic, D.
    Kanwar, A.
    Alogna, A.
    Reddy, Y. N.
    Lim, K. G.
    Shah, S.
    Borlaug, B. B.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [45] Obesity in patients with heart failure and a preserved ejection fraction
    Wajahat, R
    Titova, I
    Rumbarger, LEK
    King, DL
    Maurer, MS
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S107 - S107
  • [46] Prognosis for Patients With Heart Failure With Preserved Ejection Fraction
    Jacob, Javier
    Herrero, Pablo
    Martin-Sanchez, Francisco Javier
    Llorens, Pere
    Gil, Victor
    Miro, Oscar
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (03): : 300 - 301
  • [47] Irbesartan in patients with heart failure and preserved ejection fraction
    Camafort, Miguel
    REVISTA CLINICA ESPANOLA, 2009, 209 (10): : 514 - 515
  • [48] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease
    Wanner, Christoph
    INTERNIST, 2022, 63 (SUPPL 3): : 349 - 349
  • [49] Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
    Coats, Andrew J. S.
    Butler, Javed
    Tsutsui, Hiroyuki
    Doehner, Wolfram
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Chopra, Vijay K.
    Verma, Subodh
    Nordaby, Matias
    Iwata, Tomoko
    Nitta, Daisuke
    Ponikowski, Piotr
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (01) : 412 - 424
  • [50] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    CIRCULATION, 2022, 146
12345